According to OG Analysis, the Internet of Medical Things (IoMT) Market is estimated at USD 99.1 billion in 2026 and projected to reach USD 425.4 billion by 2034, at a reported CAGR of 19.98% during 2026–2034.

Market Overview

IoMT links connected medical equipment with software that captures, transmits and organizes device information for healthcare teams. Applications span bedside monitoring, implanted-device follow-up, wearable measurements and home-based glucose or respiratory care. A deployment typically combines medical hardware, local or wireless connectivity, data platforms and interfaces with clinical systems. Purchasers evaluate measurement performance, reliability, interoperability and alert usability. Successful implementation also depends on installation, support and clear responsibilities for reviewing incoming information. The commercial offering therefore extends beyond individual devices to include integration, maintenance and services that support their use across care settings.

Key Market Insights

● Wearable devices lead device types with an estimated 41% market share in 2026.

● Real-time monitoring leads applications with an estimated 35% market share in 2026.

● Healthcare providers represent the largest end-user segment, with an estimated 51% share in 2026.

● North America leads regional markets with an estimated 38% share in 2026.

● Asia-Pacific is projected to be the fastest-growing regional market.

Market Dynamics

● Hospital-to-home programs expand demand for connected devices that support data continuity across hospital wards, outpatient settings and patients’ homes.

● Interoperability requires agreed data structures and implementation work to connect device observations with electronic health records and existing clinical applications.

● Analytics can prioritize longitudinal measurements, but adoption depends on validated intended uses and integration with the way clinical teams review information.

● Device lifecycle support includes vulnerability management, software inventories and updates, making cybersecurity maintenance an ongoing consideration in supplier selection.

● Platform partnerships broaden portfolios by linking established medical hardware with services for data management, remote review and ongoing support.

● Home monitoring depends on usable setup, compatible devices and reliable connectivity, alongside support arrangements that accommodate patients’ capabilities and circumstances.

● Commercial adoption depends on total program costs, integration effort, user training and staff capacity to review data through defined care protocols.

Browse for More Information

https://www.oganalysis.com/industry-reports/internet-of-medical-things-iomt-market

Market Segmentation

By Device Type: Wearable Devices; Stationary Devices; Implantable Devices; Other Devices. By Application: Data Assortment and Analysis; Real-Time Monitoring; Remote Medical Assistance; Tracking and Alerts; Other Applications. By End User: Healthcare Providers; Patients; Government Authorities; Other End Users. Regions: North America; Europe; Asia-Pacific; Middle East and Africa; South and Central America.

Regional Insights

● North American opportunities center on connected monitoring within established health systems and expanding device-enabled programs for glucose, cardiac and respiratory care.

● European opportunities include hospital-at-home services and coordinated monitoring, with partnerships linking wearable devices, care platforms and clinical teams.

● Across Asia-Pacific, opportunities vary with hospital digitization, connectivity and purchasing capacity, increasing the value of adaptable implementation and local support.

● Middle Eastern, African and South American opportunities depend on affordable connectivity, reliable device servicing and programs suited to varying healthcare capacity.

Competitive Landscape

Competition involves medical-device manufacturers, clinical software providers and connectivity specialists. Suppliers differentiate through measurement capabilities, compatibility with installed equipment, reliable data exchange and ongoing service. Partnerships can widen the supported device set and extend monitoring across care locations. Procurement also depends on evidence supporting intended uses, implementation costs and security support. Connected portfolios increasingly combine monitoring or therapeutic hardware with applications for clinical review and patient engagement.

Relevant industry participants include Medtronic, Philips, GE HealthCare, Siemens Healthineers, Abbott, Dexcom, Boston Scientific and ResMed.

Recent Developments

● August 2026: Abbott announced FDA De Novo authorization for Libre Duo 10 Day, a connected system monitoring glucose and ketones, with a U.S. launch planned for later in the year.

● August 2026: Philips announced six collaborations to expand its open monitoring ecosystem, connecting wearable and out-of-hospital technologies with clinical platforms to support information continuity from hospital care to home recovery.

● July 2026: Dexcom was selected as the first participant in FDA’s TEMPO pilot, supporting real-world evaluation of a glucose health program combining biosensor readings, contextual health information and clinician software.

● June 2026: Medtronic announced an exclusive U.S. distribution agreement for Corsano Health’s FDA-cleared multiparameter wrist wearable, expanding its remote-monitoring portfolio for hospital and hospital-to-home settings.

● March 2026: GE HealthCare announced founding membership in HL7’s Caliper FHIR Accelerator, supporting collaborative work to improve medical-device data exchange and integration across healthcare systems.